# Deep Apple Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/deep-apple-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.deepappletx.com
- Total disclosed funding: $52M
- Latest round: Series A (Dec 14, 2023)
- Investors on record: 1

## About

Based in New York, US, and founded in 2022 by co-founders Brian Shoichet and Georgios Skiniotis, Deep Apple Therapeutics, Inc. operates as a medical research-based company developing novel small molecules for many disease areas, including metabolic disorders, inflammation, immunology, and endocrine diseases. In December 2023, Apple Tree Partners raised USD 52 million in Series A funding for Deep Apple Therapeutics, Inc.

Deep Apple Therapeutics, Inc. provides a discovery engine that conducts virtual screens of vast, proprietary virtual libraries, comprising billions of compounds. This approach significantly cuts drug discovery time and enhances the probability of clinical and commercial success. The company specializes in small-molecule therapeutics. Deep Apple combines deep learning, cryo-EM-enabled structural biology, AI-powered pocket extraction, molecular dynamics, and ultra-high-volume virtual screening to rapidly identify and advance novel drug candidates. In addition, the firm’s technology is Orchard, a virtual library expansion tool that employs machine learning to accelerate hit discovery. The company's programs leverage the family of G-protein coupled receptors (GPCRs), addressing a variety of applications in diseases such as obesity, inflammation, and immunology.

## Funding rounds

- Series A, Dec 14, 2023, $52M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A